← All stocks

Arbutus Biopharma Corp

ABUS Net selling
CIK 0001447028 #2587 in the set updated 21 Sep 2026
Bought (120 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$2.45M
$330.50K on a plan · $32.64K straight out of an exercise
Sold at will
$2.09M
14 of 23 sales
Net
−$2.45M
−$2.09M against sales at will

By person

12 insiders · 25 transactions

There is no salary here to measure against. Arbutus Biopharma Corp's chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sofia Michael J.
Chief Scientific Officer
$1.71M (11)
−$1.71M
2,170,769
$7.13M
−4.9%
McElhaugh Michael J.
Interim President & CEO
$501.84K (6)
−$501.84K
1,658,003
$5.44M
+19.5%
HASTINGS DAVID C
Chief Financial Officer
$95.01K (2) scheduled
−$95.01K
249,824
$820.17K
Sims Karen
Chief Medical Officer
$73.60K (2) scheduled
−$73.60K
155,494
$510.49K
+438.0%
Naftzger J. Christopher
General Counsel and CCO
$37.21K (1) scheduled
−$37.21K
140,544
$461.41K
+5,574%
MANCHESTER KEITH S
Director
$32.64K (1) scheduled
−$32.64K
46,069
$151.24K
Roivant Sciences Ltd. entity
10% owner
38,847,462
$127.54M
+142.6%
Murray Mark J.
President and CEO
341,396
$1.12M
+18.0%
Collier William H.
President and CEO
216,500
$710.77K
Howard Elizabeth
EVP, GC, Compliance
86,024
$282.42K
+427.0%
Nguyen Tuan
Chief Financial Officer
73,500
$241.30K
Androski Lindsay
President and CEO
28,000
$91.92K

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Insider
Date
Role
Action
Shares
Price
Amount
Naftzger J. Christopher
4 Feb 2025
General Counsel and CCO
Sold on a plan
11,333
$3.28
$37.21K
McElhaugh Michael J.
4 Feb 2025
Interim President & CEO
Sold on a plan
23,790
$3.28
$78.10K
Sims Karen
4 Feb 2025
Chief Medical Officer
Sold on a plan
19,348
$3.28
$63.52K
HASTINGS DAVID C
4 Feb 2025
Chief Financial Officer
Sold on a plan
22,183
$3.28
$72.83K
MANCHESTER KEITH S
14 Aug 2024
Director
Sold after exercise
8,846
$3.69
$32.64K
McElhaugh Michael J.
2 Feb 2024
Interim President & CEO
Sold on a plan
10,164
$2.31
$23.50K
Sofia Michael J.
2 Feb 2024
Chief Scientific Officer
Sold on a plan
9,982
$2.31
$23.08K
HASTINGS DAVID C
2 Feb 2024
Chief Financial Officer
Sold on a plan
9,593
$2.31
$22.18K
Sims Karen
2 Feb 2024
Chief Medical Officer
Sold on a plan
4,358
$2.31
$10.08K
Sofia Michael J.
1 Dec 2021
Chief Scientific Officer
Sell
200,000
$5.09
$1.02M
McElhaugh Michael J.
9 Feb 2021
Chief Business Officer
Sell
20,000
$5.00
$100.00K
McElhaugh Michael J.
14 Dec 2020
Chief Business Officer
Sell
10,000
$5.00
$50.03K
McElhaugh Michael J.
14 Dec 2020
Chief Business Officer
Sell
30,000
$5.00
$150.00K
McElhaugh Michael J.
23 Jul 2020
Chief Business Officer
Sell
20,000
$5.01
$100.20K
Murray Mark J.
28 Nov 2018
Director
Exercised, kept
25,000
$1.35
$33.75K
Sofia Michael J.
13 Aug 2018
Chief Scientific Officer
Sell
4,250
$9.51
$40.44K
Sofia Michael J.
11 Jul 2018
Chief Scientific Officer
Sell
10,000
$10.00
$100.00K
Sofia Michael J.
9 Jul 2018
Chief Scientific Officer
Sell
10,000
$8.91
$89.06K
Sofia Michael J.
6 Jul 2018
Chief Scientific Officer
Sell
10,000
$8.45
$84.50K
Sofia Michael J.
5 Jul 2018
Chief Scientific Officer
Sell
10,000
$8.40
$84.00K
Sofia Michael J.
3 Jul 2018
Chief Scientific Officer
Sell
10,000
$8.00
$80.00K
Murray Mark J.
17 Apr 2018
President & CEO
Exercised, kept
27,007
$0.35
$9.56K
Sofia Michael J.
3 Oct 2017
Chief Scientific Officer
Sell
10,000
$8.00
$80.00K
Sofia Michael J.
15 Aug 2017
Chief Scientific Officer
Sell indirect
20,000
$3.68
$73.50K
Sofia Michael J.
15 Aug 2017
Chief Scientific Officer
Sell indirect
10,000
$3.75
$37.50K

What was left out

Form 4 filings counted 164
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 15
Sales on a Rule 10b5-1 plan 8
Sales straight out of an exercise 1
Sales at will 14
Transactions with no price 0
Shares from compensation/vesting 24,486,044
Sales filed before the plan box existed 14
History held since 6 Oct 2016